Recognizing Canine Immune-Mediated Hemolytic Anemia: Clinical Signs and Hematobiochemical Findings

Early recognition of immune-mediated hemolytic anemia (IMHA) can significantly influence clinical decision-making and patient management. Although IMHA is a common autoimmune disorder in dogs, its clinical presentation is often nonspecific, making diagnosis challenging during the initial examination. Patients may present with signs attributable to anemia, hemolysis, or systemic inflammation, and the severity of clinical signs often depends on the rate at which anemia develops¹. A thorough physical examination supported by hematological and biochemical evaluation remains essential for identifying affected dogs and determining the extent of disease involvement. 

Recognizing the Clinical Presentation 

The history and clinical examination provide valuable clues when IMHA is suspected. Dogs commonly present with signs related to reduced oxygen-carrying capacity and the body's compensatory response to anemia. In cases where anemia develops gradually, clinical abnormalities may remain subtle until the disease becomes severe¹. 

Common clinical findings include: 

• Anorexia 

• Lethargy 

• Pale mucous membranes 

• Jaundice (icterus) 

• Hemoglobinuria resulting in port wine-colored urine 

• Bilirubinuria 

• Tachypnea 

• Tachycardia 

• Splenomegaly and hepatomegaly² 

While splenic and hepatic macrophages are the principal sites of erythrocyte destruction, enlargement of these organs is not consistently observed in every patient¹. 

Jaundice is another important clinical finding. Severe anemia may impair hepatic function, reducing bilirubin clearance while increasing bilirubin production due to accelerated erythrocyte destruction. Icterus is usually first evident on the mucous membranes before becoming apparent on the skin as bilirubin concentrations continue to rise¹. 

Approximately 50% to 70% of dogs with IMHA may also have concurrent thrombocytopenia. When immune-mediated thrombocytopenia accompanies IMHA, the condition is referred to as Evans syndrome. These patients may exhibit bleeding manifestations such as epistaxis, petechiae, ecchymoses, and melena due to reduced circulating platelet numbers³. 

Hematological Findings That Support Clinical Suspicion 

Complete blood count (CBC) remains one of the most informative laboratory investigations in dogs with suspected IMHA. Findings typically reflect an acute hemolytic crisis together with evidence of regenerative anemia and tissue hypoxia. 

A CBC commonly reveals: 

• Normocytic, normochromic regenerative anemia 

• Hematocrit ≤30% 

• Polychromasia 

• Anisocytosis 

• Nucleated red blood cells¹ 

Spherocytosis 

Spherocytes are among the most characteristic hematological findings in canine IMHA. Partial removal of antibody-coated erythrocyte membranes by splenic or hepatic macrophages transforms normal biconcave erythrocytes into smaller, spherical cells lacking central pallor. Their presence is highly suggestive of extravascular hemolysis and has been identified in 89% to 95% of affected dogs¹. 

Reticulocytosis 

Reticulocytosis reflects an active regenerative response to hemolysis. Increased circulating reticulocytes, together with nucleated RBCs, anisocytosis, and polychromasia, indicate that the bone marrow is responding appropriately to anemia¹. 

Leukocytosis 

Many dogs develop an inflammatory leukogram characterized by neutrophilia with a left shift. In severe inflammatory states, a leukoerythroblastic pattern with numerous nucleated erythrocytes may also be observed. Marked leukocytosis may indicate significant tissue injury secondary to severe anemic hypoxia¹. 

Serum Biochemistry and Urinalysis 

Biochemical abnormalities frequently accompany hematological changes and help assess the systemic impact of IMHA. 

Common findings include: 

• Increased serum bilirubin 

• Elevated lactate dehydrogenase 

• Increased blood urea nitrogen 

• Increased creatinine 

• Elevated ALT and AST 

• Decreased haptoglobin concentration¹ 

Hyperbilirubinemia results from increased bilirubin production following erythrocyte destruction, together with reduced hepatic clearance during severe anemia. In cases of intravascular hemolysis, circulating free hemoglobin binds to haptoglobin, resulting in reduced serum haptoglobin concentrations¹. 

Urinalysis further supports clinical assessment. Bilirubinuria is commonly associated with extravascular hemolysis, whereas hemoglobinuria is more suggestive of intravascular erythrocyte destruction¹. 

Bone Marrow Response¹ 

Most dogs with IMHA demonstrate an active regenerative erythroid response. However, some patients may initially lack reticulocytosis because sufficient time has not elapsed for marrow regeneration to become evident. In prolonged non-regenerative cases, immune-mediated destruction of erythroid precursor cells may impair erythropoiesis despite persistent anemia. 

Practical Clinical Insights 

• Evaluate every anemic dog systematically for evidence of both hemolysis and regeneration rather than relying on a single laboratory finding. 

• Pale mucous membranes, jaundice, hemoglobinuria, and lethargy together should heighten suspicion for IMHA and prompt further investigation. 

• Careful examination of the peripheral blood smear for spherocytes remains an important component of routine hematological assessment. 

• CBC, serum biochemistry, and urinalysis should be interpreted collectively, as each provides complementary information regarding disease severity and organ involvement. 

• Concurrent thrombocytopenia should prompt consideration of Evans syndrome, particularly in dogs presenting with spontaneous bleeding. 

Conclusion 

Canine IMHA often presents with a combination of nonspecific clinical signs and characteristic hematobiochemical abnormalities. Careful assessment of clinical presentation, supported by CBC, blood smear evaluation, serum biochemistry, urinalysis, and bone marrow findings where appropriate, enables veterinarians to recognize affected patients promptly and determine the extent of systemic involvement. A structured interpretation of these findings forms the foundation for subsequent diagnostic confirmation and therapeutic planning. 

References 

1. Karthik I, Dubey A, Swamy M, Verma Y, Jatav M, Khare A, Rakesh S. Immune mediated hemolytic anemia in dogs–an overview. Indian J Agric Allied Sci. 2022;8(4) https://www.researchgate.net/publication/377525778 

2. Manev, I. andMarincheva, V. (2018). Canine immune-mediated hemolytic anemia - brief review. Tradition and Modernity in Veterinary Medicine, 3(4): 59-64. https://www.researchgate.net/profile/Iliyan-Manev/publication/323959897 

3. Archer T, Mackin A. Diagnosis of immune-mediated hemolytic anemia. Today’s Veterinary Practice. 2013 Sep 11;7(8):32-6. https://todaysveterinarypractice.com/wp-content/uploads/sites/4/2016/09/T1307F04.pdf